> top > docs > PubMed:22410125 > annotations

PubMed:22410125 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 13-20 PR:Q8IWU5 denotes HSulf-2
T2 13-20 Q8IWU5 denotes HSulf-2
T5 35-48 CVCL_5552 denotes MCF10DCIS.com
T6 40-44 D002285 denotes DCIS
T8 40-44 D002285 denotes DCIS
T10 45-48 CHEBI:17905 denotes com
T13 65-89 D002285 denotes ductal carcinoma in situ
T14 65-89 D002285 denotes ductal carcinoma in situ
T19 114-130 D044584 denotes ductal carcinoma
T20 114-130 D044584 denotes ductal carcinoma
T25 154-178 D002285 denotes Ductal carcinoma in situ
T26 154-178 D002285 denotes Ductal carcinoma in situ
T32 180-184 CVCL_5552 denotes DCIS
T31 180-184 D002285 denotes DCIS
T33 180-184 D002285 denotes DCIS
T34 193-199 UBERON:0000310 denotes breast
T36 389-393 CVCL_5552 denotes DCIS
T35 389-393 D002285 denotes DCIS
T37 389-393 D002285 denotes DCIS
T38 406-422 D044584 denotes ductal carcinoma
T39 406-422 D044584 denotes ductal carcinoma
T42 430-437 CHEBI:24500 denotes Heparan
T43 453-460 PR:Q8IWU5 denotes HSulf-2
T44 453-460 Q8IWU5 denotes HSulf-2
T45 468-475 CHEBI:16189 denotes sulfate
T50 488-517 D019812 denotes heparan sulfate proteoglycans
T51 488-517 D019812 denotes heparan sulfate proteoglycans
T57 564-571 5224 denotes heparin
T59 564-571 235473 denotes heparin
T56 564-571 CHEBI:28304 denotes heparin
T58 564-571 D006493 denotes heparin
T60 564-571 D006493 denotes heparin
T61 564-579 GO:0008201 denotes heparin binding
T62 572-579 SO:0100018 denotes binding
T63 572-579 SO:0001091 denotes binding
T65 580-593 P08441 denotes growth factor
T66 580-593 P08072 denotes growth factor
T67 580-593 Q776B5 denotes growth factor
T68 580-593 Q6RZT5 denotes growth factor
T69 580-593 Q8V307 denotes growth factor
T70 594-603 GO:0023052 denotes signaling
T71 605-617 GO:0001525 denotes angiogenesis
T72 622-635 D063646 denotes tumorigenesis
T73 622-635 D063646 denotes tumorigenesis
T74 658-665 PR:Q8IWU5 denotes HSulf-2
T75 658-665 Q8IWU5 denotes HSulf-2
T76 669-675 UBERON:0000310 denotes breast
T77 669-682 D001943 denotes breast cancer
T78 669-682 D001943 denotes breast cancer
T81 717-730 CVCL_5552 denotes MCF10DCIS.com
T82 722-726 D002285 denotes DCIS
T84 722-726 D002285 denotes DCIS
T86 727-730 CHEBI:17905 denotes com
T88 750-759 CVCL_5552 denotes MCF10DCIS
T89 755-759 D002285 denotes DCIS
T91 755-759 D002285 denotes DCIS
T92 769-776 PR:Q8IWU5 denotes HSulf-2
T93 769-776 Q8IWU5 denotes HSulf-2
T95 798-802 CVCL_5552 denotes DCIS
T94 798-802 D002285 denotes DCIS
T96 798-802 D002285 denotes DCIS
T98 861-865 D051379 denotes mice
T100 861-865 10095 denotes mice
T97 861-865 PR:000005054 denotes mice
T99 861-865 O89094 denotes mice
T101 909-915 UBERON:0000310 denotes breast
T102 909-922 D001943 denotes breast cancer
T103 909-922 D001943 denotes breast cancer
T104 961-968 PR:Q8IWU5 denotes HSulf-2
T105 961-968 Q8IWU5 denotes HSulf-2
T107 989-993 CVCL_5552 denotes DCIS
T106 989-993 D002285 denotes DCIS
T108 989-993 D002285 denotes DCIS
T109 1007-1012 10090 denotes mouse
T110 1007-1012 D051379 denotes mouse
T112 1013-1016 CHEBI:24021 denotes fat
T113 1013-1020 UBERON:0003916 denotes fat pad
T114 1013-1020 UBERON:0001014 denotes fat pad
T116 1017-1020 O07006 denotes pad
T117 1017-1020 P33751 denotes pad
T118 1017-1020 PR:000022589 denotes pad
T119 1017-1020 C0H3U9 denotes pad
T120 1017-1020 O06837 denotes pad
T121 1017-1020 Q8X7Z8 denotes pad
T122 1017-1020 Q9X697 denotes pad
T123 1017-1020 Q9X698 denotes pad
T124 1017-1020 Q7DBA7 denotes pad
T125 1017-1020 P94404 denotes pad
T126 1017-1020 Q4R101 denotes pad
T127 1017-1020 Q9KPX2 denotes pad
T128 1017-1020 Q9S4M7 denotes pad
T129 1017-1020 P69772 denotes pad
T130 1017-1020 Q4R102 denotes pad
T131 1017-1020 Q9X696 denotes pad
T132 1017-1020 P94405 denotes pad
T133 1017-1020 P80668 denotes pad
T134 1070-1073 GO:0000974 denotes NTC
T135 1070-1073 PR:Q8SX86 denotes NTC
T136 1079-1086 PR:Q8IWU5 denotes HSulf-2
T137 1079-1086 Q8IWU5 denotes HSulf-2
T139 1100-1109 CVCL_5552 denotes MCF10DCIS
T140 1105-1109 D002285 denotes DCIS
T142 1105-1109 D002285 denotes DCIS
T143 1110-1116 UBERON:0000310 denotes breast
T144 1110-1123 D001943 denotes breast cancer
T145 1110-1123 D001943 denotes breast cancer
T146 1147-1150 GO:0000974 denotes NTC
T147 1147-1150 PR:Q8SX86 denotes NTC
T149 1151-1156 SO:0002031 denotes shRNA
T148 1151-1156 D034741 denotes shRNA
T151 1186-1191 SO:0002031 denotes shRNA
T150 1186-1191 D034741 denotes shRNA
T152 1200-1207 PR:Q8IWU5 denotes HSulf-2
T153 1200-1207 Q8IWU5 denotes HSulf-2
T155 1263-1266 PR:Q8SX86 denotes NTC
T154 1263-1266 GO:0000974 denotes NTC
T156 1271-1278 PR:Q8IWU5 denotes HSulf-2
T157 1271-1278 Q8IWU5 denotes HSulf-2
T159 1289-1298 CVCL_5552 denotes MCF10DCIS
T160 1294-1298 D002285 denotes DCIS
T162 1294-1298 D002285 denotes DCIS
T163 1308-1313 10090 denotes mouse
T164 1308-1313 D051379 denotes mouse
T166 1322-1325 CHEBI:24021 denotes fat
T165 1322-1325 UBERON:0001013 denotes fat
T167 1326-1330 UBERON:2001977 denotes pads
T171 1412-1428 D011419 denotes Propidium iodide
T172 1412-1428 D011419 denotes Propidium iodide
T173 1412-1428 CHEBI:51240 denotes Propidium iodide
T175 1466-1475 GO:0097194 denotes apoptosis
T176 1466-1475 GO:0006915 denotes apoptosis
T177 1531-1538 MGI:87853 denotes a mouse
T178 1533-1538 10090 denotes mouse
T179 1533-1538 D051379 denotes mouse
T180 1539-1554 UBERON:0012282 denotes mammary fat pad
T182 1547-1550 CHEBI:24021 denotes fat
T186 1551-1554 O07006 denotes pad
T187 1551-1554 P33751 denotes pad
T188 1551-1554 PR:000022589 denotes pad
T189 1551-1554 C0H3U9 denotes pad
T190 1551-1554 O06837 denotes pad
T191 1551-1554 Q8X7Z8 denotes pad
T192 1551-1554 Q9X697 denotes pad
T193 1551-1554 Q9X698 denotes pad
T194 1551-1554 Q7DBA7 denotes pad
T195 1551-1554 P94404 denotes pad
T196 1551-1554 Q4R101 denotes pad
T197 1551-1554 Q9KPX2 denotes pad
T198 1551-1554 Q9S4M7 denotes pad
T199 1551-1554 P69772 denotes pad
T200 1551-1554 Q4R102 denotes pad
T201 1551-1554 Q9X696 denotes pad
T202 1551-1554 P94405 denotes pad
T203 1551-1554 P80668 denotes pad
T204 1642-1652 GO:0065007 denotes regulation
T205 1656-1663 PR:Q8IWU5 denotes HSulf-2
T206 1656-1663 Q8IWU5 denotes HSulf-2
T207 1773-1779 D009369 denotes tumors
T208 1773-1779 D009369 denotes tumors
T209 1827-1835 GO:0019835 denotes necrosis
T210 1827-1835 GO:0008219 denotes necrosis
T213 1827-1835 GO:0008220 denotes necrosis
T214 1827-1835 GO:0001906 denotes necrosis
T215 1827-1835 GO:0070265 denotes necrosis
T211 1827-1835 D009336 denotes necrosis
T212 1827-1835 D009336 denotes necrosis
T216 1849-1856 D010634 denotes luminal
T217 1849-1856 D010634 denotes luminal
T218 1849-1856 CHEBI:8069 denotes luminal
T219 1857-1866 GO:0097194 denotes apoptosis
T220 1857-1866 GO:0006915 denotes apoptosis
T221 1874-1884 GO:0065007 denotes regulation
T222 1906-1909 PR:O88498 denotes Bim
T223 1906-1909 PR:O43521 denotes Bim
T224 1906-1909 PR:000002187 denotes Bim
T225 1906-1909 PR:O54918 denotes Bim
T226 1906-1909 CHEBI:33173 denotes Bim
T227 1919-1923 PR:P35875 denotes PARP
T228 1919-1923 P08469 denotes PARP
T229 1919-1923 P35875 denotes PARP
T230 1919-1923 Q11208 denotes PARP
T231 1919-1923 P14043 denotes PARP
T233 1919-1923 P55057 denotes PARP
T232 1919-1923 CHEBI:62913 denotes PARP
T236 1936-1945 P55866 denotes caspase 3
T237 1936-1945 Q8MJC3 denotes caspase 3
T238 1936-1945 Q2PFV2 denotes caspase 3
T239 1936-1945 Q08DY9 denotes caspase 3
T240 1936-1945 Q5IS54 denotes caspase 3
T241 1936-1945 Q8MKI5 denotes caspase 3
T242 1936-1945 PR:000002312 denotes caspase 3
T243 1936-1945 Q8MJU1 denotes caspase 3
T244 1936-1945 Q60431 denotes caspase 3
T245 1936-1945 P42574 denotes caspase 3
T246 1936-1945 Q5IS99 denotes caspase 3
T247 1936-1945 Q95ND5 denotes caspase 3
T248 1936-1945 P70677 denotes caspase 3
T249 1936-1945 P55213 denotes caspase 3
T235 1936-1945 D053148 denotes caspase 3
T250 1949-1956 PR:Q8IWU5 denotes HSulf-2
T251 1949-1956 Q8IWU5 denotes HSulf-2
T252 1991-1998 PR:Q8IWU5 denotes HSulf-2
T253 1991-1998 Q8IWU5 denotes HSulf-2
T254 2032-2049 GO:0005604 denotes basement membrane
T255 2032-2049 UBERON:0005769 denotes basement membrane
T259 2102-2108 UBERON:0027368 denotes matrix
T261 2102-2128 P14780 denotes matrix metalloproteinase 9
T262 2102-2128 P41246 denotes matrix metalloproteinase 9
T263 2102-2128 P41245 denotes matrix metalloproteinase 9
T264 2102-2128 P50282 denotes matrix metalloproteinase 9
T265 2102-2128 PR:000010491 denotes matrix metalloproteinase 9
T266 2102-2128 P52176 denotes matrix metalloproteinase 9
T267 2102-2128 O18733 denotes matrix metalloproteinase 9
T260 2102-2128 D020780 denotes matrix metalloproteinase 9
T268 2130-2133 CHEBI:340824 denotes MMP
T271 2130-2133 CHEBI:59761 denotes MMP
T272 2130-2135 PR:P50282 denotes MMP-9
T273 2130-2135 PR:P14780 denotes MMP-9
T274 2130-2135 P14780 denotes MMP-9
T275 2130-2135 PR:P41245 denotes MMP-9
T276 2130-2135 P41246 denotes MMP-9
T277 2130-2135 P41245 denotes MMP-9
T278 2130-2135 PR:P52176 denotes MMP-9
T279 2130-2135 P50282 denotes MMP-9
T281 2130-2135 PR:000010491 denotes MMP-9
T282 2130-2135 P52176 denotes MMP-9
T283 2130-2135 O18733 denotes MMP-9
T280 2130-2135 GO:0004229 denotes MMP-9
T284 2161-2172 GO:0009056 denotes degradation
T286 2176-2196 GO:0031012 denotes extracellular matrix
T287 2190-2196 UBERON:0027368 denotes matrix
T288 2264-2271 PR:Q8IWU5 denotes HSulf-2
T289 2264-2271 Q8IWU5 denotes HSulf-2
T290 2303-2308 D006801 denotes human
T291 2309-2315 UBERON:0000310 denotes breast
T292 2309-2322 D001943 denotes breast cancer
T293 2309-2322 D001943 denotes breast cancer
T294 2341-2351 GO:0065007 denotes regulation
T295 2355-2362 PR:Q8IWU5 denotes HSulf-2
T296 2355-2362 Q8IWU5 denotes HSulf-2
T297 2372-2381 GO:0051235 denotes retention
T299 2397-2401 CVCL_5552 denotes DCIS
T298 2397-2401 D002285 denotes DCIS
T300 2397-2401 D002285 denotes DCIS
T302 2432-2436 CVCL_5552 denotes DCIS
T301 2432-2436 D002285 denotes DCIS
T303 2432-2436 D002285 denotes DCIS
T304 2516-2523 PR:Q8IWU5 denotes HSulf-2
T305 2516-2523 Q8IWU5 denotes HSulf-2
T307 2566-2570 CVCL_5552 denotes DCIS
T306 2566-2570 D002285 denotes DCIS
T308 2566-2570 D002285 denotes DCIS

DisGeNET

Id Subject Object Predicate Lexical cue
T0 1919-1923 gene:142 denotes PARP
T1 1820-1826 disease:C0221228 denotes comedo
T2 1919-1923 gene:1302 denotes PARP
T3 1820-1826 disease:C0221228 denotes comedo
R1 T0 T1 associated_with PARP,comedo
R2 T2 T3 associated_with PARP,comedo

Allie

Id Subject Object Predicate Lexical cue
SS1_22410125_2_0 154-178 expanded denotes Ductal carcinoma in situ
SS2_22410125_2_0 180-184 abbr denotes DCIS
SS1_22410125_3_0 397-422 expanded denotes invasive ductal carcinoma
SS2_22410125_3_0 424-427 abbr denotes IDC
SS1_22410125_4_0 488-517 expanded denotes heparan sulfate proteoglycans
SS2_22410125_4_0 519-524 abbr denotes HSPGs
SS1_22410125_9_0 1050-1068 expanded denotes Non-target control
SS2_22410125_9_0 1070-1073 abbr denotes NTC
SS1_22410125_15_0 2102-2128 expanded denotes matrix metalloproteinase 9
SS2_22410125_15_0 2130-2135 abbr denotes MMP-9
AE1_22410125_2_0 SS1_22410125_2_0 SS2_22410125_2_0 abbreviatedTo Ductal carcinoma in situ,DCIS
AE1_22410125_3_0 SS1_22410125_3_0 SS2_22410125_3_0 abbreviatedTo invasive ductal carcinoma,IDC
AE1_22410125_4_0 SS1_22410125_4_0 SS2_22410125_4_0 abbreviatedTo heparan sulfate proteoglycans,HSPGs
AE1_22410125_9_0 SS1_22410125_9_0 SS2_22410125_9_0 abbreviatedTo Non-target control,NTC
AE1_22410125_15_0 SS1_22410125_15_0 SS2_22410125_15_0 abbreviatedTo matrix metalloproteinase 9,MMP-9

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-139 DRI_Background denotes Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
T2 145-302 DRI_Background denotes DUCTION: Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous group of proliferative cellular lesions that have the potential to become invasive.
T3 303-429 DRI_Background denotes Very little is known about the molecular alterations involved in the progression from DCIS to invasive ductal carcinoma (IDC).
T4 430-636 DRI_Background denotes Heparan endosulfatase (HSulf-2) edits sulfate moieties on heparan sulfate proteoglycans (HSPGs) and has been implicated in modulating heparin binding growth factor signaling, angiogenesis and tumorigenesis.
T5 637-716 DRI_Background denotes However, the role of HSulf-2 in breast cancer progression is poorly understood.
T6 717-935 DRI_Background denotes MCF10DCIS.com cells (referred as MCF10DCIS) express HSulf-2 and form comedo type DCIS and progress to IDC when transplanted in immune-deficient mice and, therefore, is an ideal model to study breast cancer progression.
T7 936-1040 DRI_Approach denotes We evaluated the role of HSulf-2 in progression from DCIS to IDC using mouse fat pad mammary xenografts.
T8 1050-1174 DRI_Background denotes Non-target control (NTC) and HSulf-2 knockdown in MCF10DCIS breast cancer cells were achieved by NTC shRNA and two different
T9 1175-1191 Token_Label.OUTSIDE denotes lentiviral shRNA
T10 1192-1221 DRI_Background denotes against HSulf-2 respectively.
T11 1222-1331 DRI_Background denotes Xenografts were established by injecting NTC and HSulf-2 deficient MCF10DCIS cells in mouse mammary fat pads.
T12 1332-1515 DRI_Background denotes Xenografts were subjected to H&E staining for morphological analysis, TUNEL and Propidium iodide staining (to determine the extent of apoptosis), Western blot analysis and zymography.
T13 1525-1740 DRI_Approach denotes Using a mouse mammary fat pad derived xenograft model, we observed that compared to control treated xenografts, down-regulation of HSulf-2 was associated with significant delays in growth at Week 7 (P-value < 0.05).
T14 1741-1977 DRI_Background denotes Histological examination of the tumors demonstrated substantial differences in comedo necrosis, with marked luminal apoptosis and up-regulation of apoptotic markers Bim, cleaved PARP and cleaved caspase 3 in HSulf-2 depleted xenografts.
T15 1978-2229 DRI_Outcome denotes Furthermore, HSulf-2 depleted xenografts retained the basement membrane integrity with decreased activity and expression of matrix metalloproteinase 9 (MMP-9), an enzyme critical for degradation of extracellular matrix compared to nontargeted control.
T16 2242-2335 DRI_Outcome denotes Our data suggest that HSulf-2 expression may be critical for human breast cancer progression.
T17 2336-2444 DRI_Background denotes Down-regulation of HSulf-2 leads to retention of comedo type DCIS and delays the progression of DCIS to IDC.
T18 2445-2578 DRI_Approach denotes Further studies are necessary to determine if therapeutic targeting of HSulf-2 expression might delay the progression of DCIS to IDC.

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 154-1040 BACKGROUND denotes Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous group of proliferative cellular lesions that have the potential to become invasive. Very little is known about the molecular alterations involved in the progression from DCIS to invasive ductal carcinoma (IDC). Heparan endosulfatase (HSulf-2) edits sulfate moieties on heparan sulfate proteoglycans (HSPGs) and has been implicated in modulating heparin binding growth factor signaling, angiogenesis and tumorigenesis. However, the role of HSulf-2 in breast cancer progression is poorly understood. MCF10DCIS.com cells (referred as MCF10DCIS) express HSulf-2 and form comedo type DCIS and progress to IDC when transplanted in immune-deficient mice and, therefore, is an ideal model to study breast cancer progression. We evaluated the role of HSulf-2 in progression from DCIS to IDC using mouse fat pad mammary xenografts.
T2 1050-1515 METHODS denotes Non-target control (NTC) and HSulf-2 knockdown in MCF10DCIS breast cancer cells were achieved by NTC shRNA and two different lentiviral shRNA against HSulf-2 respectively. Xenografts were established by injecting NTC and HSulf-2 deficient MCF10DCIS cells in mouse mammary fat pads. Xenografts were subjected to H&E staining for morphological analysis, TUNEL and Propidium iodide staining (to determine the extent of apoptosis), Western blot analysis and zymography.
T3 1525-2229 RESULTS denotes Using a mouse mammary fat pad derived xenograft model, we observed that compared to control treated xenografts, down-regulation of HSulf-2 was associated with significant delays in growth at Week 7 (P-value < 0.05). Histological examination of the tumors demonstrated substantial differences in comedo necrosis, with marked luminal apoptosis and up-regulation of apoptotic markers Bim, cleaved PARP and cleaved caspase 3 in HSulf-2 depleted xenografts. Furthermore, HSulf-2 depleted xenografts retained the basement membrane integrity with decreased activity and expression of matrix metalloproteinase 9 (MMP-9), an enzyme critical for degradation of extracellular matrix compared to nontargeted control.
T4 2242-2578 CONCLUSIONS denotes Our data suggest that HSulf-2 expression may be critical for human breast cancer progression. Down-regulation of HSulf-2 leads to retention of comedo type DCIS and delays the progression of DCIS to IDC. Further studies are necessary to determine if therapeutic targeting of HSulf-2 expression might delay the progression of DCIS to IDC.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 669-682 HP_0003002 denotes breast cancer
T2 669-682 HP_0100013 denotes breast cancer
T3 676-682 HP_0002664 denotes cancer
T4 844-860 HP_0002721 denotes immune-deficient
T5 909-922 HP_0003002 denotes breast cancer
T6 909-922 HP_0100013 denotes breast cancer
T7 916-922 HP_0002664 denotes cancer

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
22410125-0#13#20#gene55959 13-20 gene55959 denotes HSulf-2
22410125-0#65#89#diseaseC0007124 65-89 diseaseC0007124 denotes ductal carcinoma in situ
22410125-0#105#130#diseaseC1134719 105-130 diseaseC1134719 denotes invasive ductal carcinoma
22410125-11#178#182#gene1302 1919-1923 gene1302 denotes PARP
22410125-11#178#182#gene142 1919-1923 gene142 denotes PARP
22410125-11#79#85#diseaseC0221228 1820-1826 diseaseC0221228 denotes comedo
22410125-13#22#29#gene55959 2264-2271 gene55959 denotes HSulf-2
22410125-13#67#80#diseaseC0006142 2309-2322 diseaseC0006142 denotes breast cancer
22410125-13#67#80#diseaseC0678222 2309-2322 diseaseC0678222 denotes breast cancer
22410125-14#19#26#gene55959 2355-2362 gene55959 denotes HSulf-2
22410125-14#49#65#diseaseC0334369 2385-2401 diseaseC0334369 denotes comedo type DCIS
22410125-15#71#78#gene55959 2516-2523 gene55959 denotes HSulf-2
22410125-15#129#132#diseaseC1449563 2574-2577 diseaseC1449563 denotes IDC
22410125-3#23#30#gene55959 453-460 gene55959 denotes HSulf-2
22410125-3#192#205#diseaseC0596263 622-635 diseaseC0596263 denotes tumorigenesis
13#20#gene5595965#89#diseaseC0007124 22410125-0#13#20#gene55959 22410125-0#65#89#diseaseC0007124 associated_with HSulf-2,ductal carcinoma in situ
13#20#gene55959105#130#diseaseC1134719 22410125-0#13#20#gene55959 22410125-0#105#130#diseaseC1134719 associated_with HSulf-2,invasive ductal carcinoma
178#182#gene130279#85#diseaseC0221228 22410125-11#178#182#gene1302 22410125-11#79#85#diseaseC0221228 associated_with PARP,comedo
178#182#gene14279#85#diseaseC0221228 22410125-11#178#182#gene142 22410125-11#79#85#diseaseC0221228 associated_with PARP,comedo
22#29#gene5595967#80#diseaseC0006142 22410125-13#22#29#gene55959 22410125-13#67#80#diseaseC0006142 associated_with HSulf-2,breast cancer
22#29#gene5595967#80#diseaseC0678222 22410125-13#22#29#gene55959 22410125-13#67#80#diseaseC0678222 associated_with HSulf-2,breast cancer
19#26#gene5595949#65#diseaseC0334369 22410125-14#19#26#gene55959 22410125-14#49#65#diseaseC0334369 associated_with HSulf-2,comedo type DCIS
71#78#gene55959129#132#diseaseC1449563 22410125-15#71#78#gene55959 22410125-15#129#132#diseaseC1449563 associated_with HSulf-2,IDC
23#30#gene55959192#205#diseaseC0596263 22410125-3#23#30#gene55959 22410125-3#192#205#diseaseC0596263 associated_with HSulf-2,tumorigenesis